The oral
anticoagulant phenindione [2-phenyl-1H-
indene-1,3(2H)-dione] is associated with
hypersensitivity reactions in 1.5 to 3% of patients, the pathogenesis of which is unclear. We describe a patient who developed a severe
hypersensitivity reaction that involved both the skin and lungs. A lymphocyte transformation test showed proliferation of T-cells from the hypersensitive patient, but not from four controls on exposure to
phenindione in vitro. Drug-specific T-cell clones were generated and characterized in terms of their phenotype, functionality, and mechanism of antigen presentation. Forty-three
human leukocyte antigen class II restricted CD4(+) alphabeta T-cell clones were identified. T-cell activation resulted in the secretion of
interferon-gamma and
interleukin-5. Five of seven clones proliferated with
phenindione alone, whereas two clones also proliferated with
2-phenylindene. Certain T-cell clones were also stimulated by R- and S-
warfarin; computer modeling revealed that
warfarin can adopt a
phenindione-like structure.
Phenindione was presented to T-cells via two pathways: first, bound directly to major histocompatibility complex and second, bound to a processed
peptide. Our data show that CD4(+) T-cells are involved in the pathophysiology of
phenindione hypersensitivity. There may be cross-sensitivity with
warfarin in some
phenindione hypersensitive patients.